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Abstract. Recent reports indicate that the alterations in the p16
and pRb pathways can influence tumour progression and poor
prognosis in several tumours. The objective of this study was to
analyse p16 and pRb expression in161 patients with malignant
fibrous histiocytomas (MFH). By immunohistochemistry, p16
and pRb were demonstrated in 25% and 56% of MFH,
respectively. Cox regression analysis demonstrated an
independent prognostic influence of both genes. Generally, the
loss of p16 and pRb expression correlated with poorer prognosis.
Promoter methylation of p16 was found in 16/42 of p16 negative
MFH and of pRb in 2/42 of pRb-negative MFH. It can be
concluded that p16 and pRb alterations play an important role
in the progression of soft tissue sarcomas.
Malignant fibrous histiocytoma (MFH) belongs to the group
of malignant soft tissue tumours and represents the most
common malignant soft tissue tumour of the late adulthood (1-
3). Not only the subtype classification, but other
histopathological features and factors can be helpful in
establishing the prognosis and therapeutic strategy for each
individual tumour. Recent tumour biological investigations
have shown that tumour development can be caused by a series
of genetic alterations which specifically comprise changes in
ploidy status, proliferation and tumour suppressor gene
defects, e.g., the mutated p53 or retinoblastoma gene (4-6).
The retinoblastoma gene intervenes in cell cycle
regulation and encodes a 105 kDa phosphoprotein, which
accumulates in the cell nucleus. Both the cell content of
retinoblastoma gene protein as well as phosphorylation of
the protein are cell-cycle dependent. It is assumed that the
under-phosphorylated form of pRb involves the functionally
active, proliferation-inhibiting protein in the G0-middle G1
phase (7-9).
Another cell cycle regulator is p16. P16 is also called
INK4/MTS1 and acts as a tumour suppressor gene. The
negative influence of p16 on proliferation has been
reported. P16 is known to indirectly inhibit the
phosphorylation of pRb (10, 11).
The main objective of this study was to examine the
prognostic relevance of the expression of cell cycle
regulators (pRb, p16) in malignant fibrous histiocytomas. In
order to elucidate the reasons for a lack of p16 (pRb)
protein expression in samples studied, an analysis of
promoter methylation for both genes was performed.
Materials and methods
Patient characteristics. A well-characterised cohort of 161 primary
MFHs, corresponding to patients treated at the teaching hospitals
of the University of Göttingen and the University of Krakow
between 1992 and 2001, was the focus of this study. There were no
differences between patients treated in Poland (n=116) and
Germany (n=45) with respect to disease-related survival (log-rank
test). The age of the patients ranged between 4 and 90 years
(mean 61 years); 45% of the MFH patients were females and 55%
were males. 
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The anatomic localisation of these tumours was distributed as
follows: head and neck (n=27), upper extremities (n=19), lower
extremities (n=86) and trunk (n=29). Thirty-six tumours (22%)
showed superficial localisation, while 117 (73%) had deep
localisation. Tumour depth could not be determined in 8 cases.
The size of the tumours ranged between 0.6 and 36 cm (median=8
cm). Thirty-nine (24%) of the neoplasms were assigned to
pathological stage pT1 and 122 (76%) tumours to pT2. In 43
patients (27%), distant metastases were clinically present at the
time of the primary diagnosis. In 2 patients, locoregional lymph
node metastases were assessed by histopathology. All patients
were observed from the time of diagnosis up to the end of the
study period (October 2001), and the disease-related survival
within this period was documented. Non-MFH-related fatalities
were excluded from the investigation. The ethical approach of this
study was aproved by the Ethical Center of the Adam Mickiewicz
University in Poznan, Poland. 
Immunohistochemistry. The tumour tissue was routinely fixed in
3.6% formaldehyde and embedded in paraplast. Three-Ìm thick
serial sections were prepared by the same technician to ensure that
the quality of the sections remained consistent. The histological
sections were mounted on uncoated slides and were deparaffinated
by xylol and then transferred to a descending alcohol series and
rinsed with distilled water. The following antibodies were utilised
for this study: mouse monoclonal antibody against human p16,
clone G175-405 and mouse monoclonal antibody against
retinoblastoma protein (pRb) clone G3-245 (both antibodies from
Pharmingen, San Diego, USA). 
The immunohistochemical reactions in the paraffin-
embedded tumour tissue were carried out using the Stravigen
Multilink kit (Biogenex Laboratories, Hamburg, Germany).
Before incubation with primary antibodies, the sections were
heated for 10 min on a heat plate (85ÆC) in citrate buffer
(pH=6). Afterwards, incubation with the primary antibodies was
carried on overnight at 4ÆC at an antibody concentration of 1:20
for retinoblastoma protein and 1:50 for p16. The histological
specimens were then rinsed with Tris buffer solution and
incubated at room temperature with link (Stravigen Multilink)
for 45 min. After the detection reaction was performed using a
label (Stravigen Multilink) in combination with chromogen fast
red (Biogenex Laboratories), the nuclei were counterstained
with haematoxylin. In control reactions, primary antibodies were
omitted. The sections were evaluated by CAS200 image analysis
system and the results were expressed as percentages of
immunolabeled cells (indices).
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Figure 1. A) P16-positive cells in malignant fibrous histiocytomas. B) Retinoblastoma positivity in malignant fibrous histiocytomas. C) Kaplan-Meier
survival curves for p16-positive and -negative malignant fibrous histiocytoma (MFH) patients. D) Kaplan-Meier survival curves demonstrating the
relationship between pRb expression and survival time of MFH patients. Note that patients were divided in 3 groups: i) cases without pRb expression; ii)
cases with low expression (1-20%); and iii) cases with high expression (>20%).
Analysis of p16 and pRb promoter methylation. The probes were
excised from the paraffin blocks containing the tumour tissue for
histopathological diagnosis. One Ìg of DNA isolated from MFH
and non-neoplastic control tissue was treated with sodium
bisulfite using the CpGenome DNA Modification Kit (Intergen
Company, Oxford, UK) according to the manufacturer's
instructions. Two Ìl of modified DNA (1/5 volume) were used for
PCR amplification. The primers were: p16 sense 5’-TTA TTA
GAG GGT GGG GCG GAT CGC-3’ and anti-sense 5’-GAC
CCC GAA CCG CGA CCG TAA-3’ for methylated sequences,
p16 sense 5’-TTA TTA GAG GGT GGG GTG GAT TGT-3’ and
anti-sense 5’-CAA CCC CAA ACC ACA ACC ATA A-3’ for
non-methylated sequences, pRb sense 5’-GGG AGT TTC GCG
GAC GTG AC-3’ and anti-sense 5’-ACG TCG AAA CAC GCC
CCG-3’ for methylated sequences, pRb sense 5’-GGG AGT TTT
GTG GAT GTG AT-3’ and anti-sense 5’-ACA TCA AAA CAC
ACC CCA-3’ for non-methylated sequences. PCR conditions
were those described by Chim et al. (12). The PCR fragments
were separated on a 3% agarose gel. 
Statistics. The data were analysed using the statistical analysis
system (SAS, Version 7.5) on an IBM-compatible PC under
windows XP and had been previously scanned into the spread sheet
(Microsoft Excel XP), where they were made available to the
statistics program via an ODBC (open database connectivity).
The median and the other quantiles were calculated for all
expression indices. The data were presented as box-plots. Mann-
Whitney-U-tests were used for the paired group comparisons. The
Kaplan-Meier method was employed to calculate the survival rates
(13). Cox regression was the multivariate method used for the
predicting the survival rate based on several parameters (14).
Results
Immunohistochemical results. The tumour suppressor gene
protein p16 was localised in nuclei by immunohistochemistry
(Figure 1A). P16 expression was found in 25% of the MFH
cases. P16 expression was higher in grade II tumours than in
grade I tumours. The p16 index in grade III tumours was as
low as in grade I MFH (Table I). 
The reaction product for the retinoblastoma gene protein
was detected in the nuclei (Figure 1B). In the control
reactions, the retinoblastoma gene protein antibody
selectively labelled the epithelial cells of the epidermis with
suprabasal localisation. Retinoblastoma gene expression was
found in 56% of the sarcomas investigated. The pRb index
varied between 0 and 95% (median 1). Grade II tumours
showed the lowest pRb expression (median 0) and grade III
the highest index (median 19) (Table I).
Relationship between p16 and pRb expression and survival rates.
Cases of MFH with an expression of p16 (index>0) and a lack
of p16 expression (index=0) did not differ significantly with
regard to the probability of survival (Figure 1C). Cases of
MFH with a high expression of the pRb (index>20) showed a
lower probability of survival than cases with a median (index
1-20) or low expression (index=0) (Figure 1D). 
Likewise, the combination of p16 and pRb showed that
the highest 5-year-survival rates were observed in patients
with zero values for both parameters. An exact ¯2-test
showed that the difference in 5-year-survival rates were
significant (p<0.001). Moreover, it was shown that patients
for whom these parameters were normal (p16=0 and
pRb=0) had the significantly highest 5-year survival rates of
the sample (p=0.004), as verified by ¯2 analysis.
The results of the Cox regression for predicting survival
based on categorised cell-cycle regulator (CCR) indices (p16,
pRb), showed, in both forward and backward parameter
selection models, an independent prognostic role of p16 and
pRb in malignant fibrous histiocytomas (Table II).
Relationship between p16 and pRb expression and promoter
methylation. Promoter methylation of p16 and pRb was
analysed in 42 p16- and pRb-negative MFH. Sixteen out of
42 cases investigated contained hypermethylated p16
promoter sequences. In contrast, only 2 cases revealed pRb
methylation (Figure 2). 
Discussion
The present study investigated 161 cases provided by the
Pathological Institutes at the University of Göttingen and
the University of Krakow. Comparatively speaking, the
processed tumour samples belong to one of the largest
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Table I. P16 and pRb indicates in MFH primary tumors in relation to histopathological grade of malignancy.
Parameter Grade Minimum 25th Percentile Median 75th Percentile Maximum
p16 index I 0 0 0 0 90
II 0 0 0 30 96
III 0 0 0 1 85
pRb index I 0 0 1 20 60
II 0 0 0 8 95
III 0 0 19 40 90
published MFH series that has been examined utilizing
special techniques. The patients samples of other studies,
i.e., Weiss and Enzinger, Pezzi et al., Hashimoto et al. and
Doussal et al. were more extensive, but were only
investigated with regard to the prognostic relevance of
grading parameters (15-18).
In this study, the association between the altered expression
of p16 and pRb and patients survival rate was demonstrated.
Both markers demonstrated an independent influence on
survival, as confirmed by Cox regression analysis. 
It is well known that loss of expression of p16 and pRb is
either connected with mutation or with the methylation of
promoter region. Mutations that disable the retinoblastoma
pathway are common in human cancer. Cells with an altered
retinoblastoma gene pathway produce aberrant Mad2
expression and mitotic defects leading to aneuploidy (19).
These mutations promote tumour development by
deregulating the E2F family transcription factors leading to
uncontrolled cell proliferation. 
In this study, loss of p16 and pRb expression correlated with
promoter methylation of these genes. This observation was
especially true for p16. Defects in p16 and pRb are very often
simultaneous as reported for several tumours (20) and also
confirmed by this study. Our results demonstrate p16 promoter
methylation in approximately 35% of p16-negative MFH and
are in accordance with the results obtained on other sarcomas.
The promoter methylation of p16 was reported for highly
malignant chondrosarcomas (21). The methylation of the p14
and p16 promoter region was also reported in 1 out of 6
human osteosarcoma cell lines. In contrast, alterations of the
retinoblastoma pathway were reported in up to 80% of
osteosarcoma cases, suggesting that deregulating the G1 to S
cell cycle checkpoint may be an almost constant change in the
pathogenesis of osteosarcomas (22). 
In the group of chondrosarcomas all tumours that showed
chromosome 9 alterations, also showed loss of
heterozygosity and p16 expression. A lack of correlation
between LOH, promoter methylation and protein
expression indicated that a locus other than CDKN2a/p16
must be the target of LOH (23). A correlation between p16
protein expression and tumour grading indicated that loss
of p16 expression may be an important event during tumour
progression. 
Inactivation of the p16 gene in leiomyosarcomas of soft
tissue was correlated with decreased protein expression of
p16, promoter methylation and poor prognosis. Eight out of
15 cases with decreased expression of p16 revealed
methylation of promoter region (24). 
P16 showed an aberrant promoter methylation in 12 out
of 19 cases of primary angiosarcoma of the liver and
influenced poor prognosis (25). The absence of p16
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Table II. Results of the Cox regression for predicting survival based on categorized CCR indices (p16, pRb).
Forward parameter selection
Remaining independent P-value Change of hazard rate Lower bound of Upper bound of 
prognostic parameters per unit of parameter 95% confidence 95% confidence
p16 index 0.003 1.1% 0.4% 1.9%
pRb index 0.001 2.2% 1.3% 3.2%
Backward parameter selection
Remaining independent P-value Change of hazard rate Lower bound of Upper bound of 
prognostic parameters per unit of parameter 95% confidence 95% confidence
p16 index 0.019 0.9% 0.2% 1.7%
pRb index 0.001 2.3% 1.4% 3.2%
CCR: cell-cycle regulator.
Figure 2. Analysis of the p16/ pRb promoter methylation status in
malignant fibrous histiocytoma samples. The results of four samples
lacking expression of both, p16 and pRb are shown. The PCR fragments
resulting from the DNA extracted and modified by bisulfite treatment were
separated on 2% agarose gel. Data show that sarcoma samples B, C and
D contain hypermethylated p16 promoter sequences. In contrast, only
sample C reveals pRb methylation. 
protein could have not only influence on prognosis but
also on the result of therapy. The absence of the p16
protein led to higher glucocorticoid receptor
transactivation activity and reduced cell sensitivity to
dexamethasone (26). 
In conclusion, the results of the present study
demonstrate for the first time, an independent prognostic
role of p16 and pRb in MFH. Methylation of promoter
region of these genes was also demonstrated and was found,
especially in the case of p16, to correlate with poor
prognosis of patients with MFH.
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